David Thompson - CREMETRSBI DL-001 Chief Executive Officer
| WY52 Stock | EUR 1.70 0.00 0.00% |
CEO
David Thompson is Chief Executive Officer of CREMECOMTRSBI DL 001 since 2019.
| Age | 55 |
| Tenure | 6 years |
| Phone | 972-349-3200 |
| Web | http://www.cimcommercial.com |
David Thompson Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Thompson against CREMETRSBI DL-001 stock is an integral part of due diligence when investing in CREMETRSBI DL-001. David Thompson insider activity provides valuable insight into whether CREMETRSBI DL-001 is net buyers or sellers over its current business cycle. Note, CREMETRSBI DL-001 insiders must abide by specific rules, including filing SEC forms every time they buy or sell CREMETRSBI DL-001'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Thompson over two months ago Disposition of 295 shares by David Thompson of American Financial subject to Rule 16b-3 | ||
David Thompson over a year ago Bona fide gift to David Thompson of 100000 shares of American Financial subject to Section 16 |
CREMETRSBI DL-001 Management Efficiency
The company has return on total asset (ROA) of 0.0151 % which means that it generated a profit of $0.0151 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.014 %, meaning that it generated $0.014 on every $100 dollars invested by stockholders. CREMETRSBI DL-001's management efficiency ratios could be used to measure how well CREMETRSBI DL-001 manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CEO Age | ||
| Michael Connolly | COUSINS PTIES INC | 42 | |
Management Performance
| Return On Equity | 0.014 | |||
| Return On Asset | 0.0151 |
CREMECOMTRSBI DL 001 Leadership Team
Elected by the shareholders, the CREMETRSBI DL-001's board of directors comprises two types of representatives: CREMETRSBI DL-001 inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CREMETRSBI. The board's role is to monitor CREMETRSBI DL-001's management team and ensure that shareholders' interests are well served. CREMETRSBI DL-001's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CREMETRSBI DL-001's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jan Salit, President Secretary | ||
| Frank Golay, Independent Director | ||
| Avi Shemesh, Director | ||
| Avraham Shemesh, Director | ||
| David Thompson, Chief Executive Officer | ||
| Robert Cresci, Independent Director | ||
| Kelly Eppich, Independent Director | ||
| Douglas Bech, Independent Director | ||
| Richard Ressler, Chairman of the Board | ||
| Shaul Kuba, Director | ||
| Nathan DeBacker, Chief Financial Officer |
CREMETRSBI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CREMETRSBI DL-001 a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.014 | |||
| Return On Asset | 0.0151 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.16 % | |||
| Shares Outstanding | 22.74 M | |||
| Shares Owned By Insiders | 13.49 % | |||
| Shares Owned By Institutions | 59.07 % | |||
| Price To Earning | 4.83 X | |||
| Revenue | 101.34 M | |||
| Gross Profit | 42.62 M |
Currently Active Assets on Macroaxis
Other Information on Investing in CREMETRSBI Stock
CREMETRSBI DL-001 financial ratios help investors to determine whether CREMETRSBI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CREMETRSBI with respect to the benefits of owning CREMETRSBI DL-001 security.